by Jeff Elton
Value-based reimbursement and contracting will become mainstream as reimbursement authorities move away from ‘cost’ as the focus towards ‘value.’
Most physicians are likely to overestimate their own patients’ adherence rates, according to a Healthprize survey.
It took a while, but the pharma industry is finally becoming aware that digital approaches may hold the key to transforming the way they market drugs and interact with their customers.
Healthcare spending in China has more than doubled from $156bn in 2006 to $357bn in 2011 and is estimated to reach $1tn by 2020 – about 6 per cent of the country’s GDP.
In order to remain competitive, pharmaceutical companies must shift their focus to smaller, more targeted patient populations.
FORUM Pharmaceuticals CEO and President Deborah Dunsire made the move from the oncology sphere into dementia-related illnesses. She tells Danielle Barron why she likes to stay at the cutting edge of research, while always keeping her eye on the prize – better outcomes for patients.
by Anonymous (not verified)
Working at a business intelligence company, I spend a lot of time at conferences and obviously I come across some stellar presentations. The good news is that's its all entirely coachable.
Changes in healthcare delivery are rapidly undermining traditional pharmaceutical commercial models. Customers are fewer and larger as hospitals consolidate into integrated delivery networks in the face of rising cost pressures, stiffer financial penalties and the imperatives of healthcare reform.
Dr Nicola Davies speaks to Mette Aagaard Hertz, Corporate Vice President at Novo Nordisk and Head of Human Resources in Research and Development, about pharma’s responsibility to maintain high standards in the fight against global health problems.
In January I was ‘treated’ by 10 HCPs in 7 days and more than 100 patients in 24 hours. The medics managed my physical state; the patients guided my psychological well-being, helping me reach decisions and an understanding more readily by sharing their information and experiences.
In the 3rd installment of Rethinking pharma, Dr Andree Bates talks about value creation and why she thinks pharma is giving its value away.
New columnist, Jeffrey Frick shares insights on the Chinese healthcare market.
The clinical trial process is a costly and integral part of bringing a drug to market, but does it have to be carried out the way it is currently? Is there a better way?